
The study revealed that CBX3 overexpression worsens patient survival and increases resistance to Irinotecan and Oxaliplatin. CBX3 inhibits ferroptosis via the NRF2 pathway by suppressing CUL3-mediated NRF2 degradation, with GPX2 as a key downstream target. NRF2 inhibitor ML385 restores ferroptosis and overcomes chemoresistance in PDX models, highlighting the CBX3/NRF2/GPX2 axis as a promising therapeutic target.
Like
Save
Share